User profiles for Juthathip Mongkolsapaya

Juthathip Mongkolsapaya

nuffield department of medicine University of Oxford
Verified email at well.ox.ac.uk
Cited by 22511

New insights into the immunopathology and control of dengue virus infection

G Screaton, J Mongkolsapaya, S Yacoub… - Nature Reviews …, 2015 - nature.com
Dengue virus poses a major threat to global public health: two-thirds of the world's population
is now at risk from infection by this mosquito-borne virus. Dengue virus causes a range of …

The immune response against flaviviruses

JL Slon Campos, J Mongkolsapaya, GR Screaton - Nature immunology, 2018 - nature.com
Arthropod-borne flaviviruses are important human pathogens that cause a diverse range of
clinical conditions, including severe hemorrhagic syndromes, neurological complications …

[HTML][HTML] Antibodies and tuberculosis

AJ Jacobs, J Mongkolsapaya, GR Screaton… - Tuberculosis, 2016 - Elsevier
Tuberculosis (TB) remains a major public health problem internationally, causing 9.6 million
new cases and 1.5 million deaths worldwide in 2014. The Bacillus Calmette-Guérin vaccine …

[PDF][PDF] Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum

…, L Stafford, EE Fry, J Huo, J Mongkolsapaya… - Cell, 2022 - cell.com
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA.1 …

[HTML][HTML] Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera

…, E Barnes, SJ Dunachie, EE Fry, J Mongkolsapaya… - Cell, 2021 - cell.com
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
began when the first sequence was published, and this forms the basis for …

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

…, P Klenerman, GR Screaton, J Mongkolsapaya… - Nature …, 2020 - nature.com
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
and therapeutics will depend on understanding viral immunity. We studied T cell memory …

[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum

…, MC Nunes, P Goulder, EE Fry, J Mongkolsapaya… - Cell, 2021 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…

[PDF][PDF] Antibody evasion by the P. 1 strain of SARS-CoV-2

…, RJG Hulswit, TA Bowden, EE Fry, J Mongkolsapaya… - Cell, 2021 - cell.com
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. …

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4 …

…, L Cantrell, W Dejnirattisai, X Liu, J Mongkolsapaya… - The Lancet, 2022 - thelancet.com
Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has
been widely used in a two-dose schedule. We assessed whether a third dose of the …

Cross-reacting antibodies enhance dengue virus infection in humans

…, K Chawansuntati, P Malasit, J Mongkolsapaya… - Science, 2010 - science.org
Dengue virus co-circulates as four serotypes, and sequential infections with more than one
serotype are common. One hypothesis for the increased severity seen in secondary …